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Abstract
Purpose Response to anticancer therapy is believed to be
directly related to the concentration of the anticancer drug
in the tumor itself. Assessment of intra-tumor drug pharma-
cokinetics can be helpful to gain more insight into mecha-
nisms involved in the (in)sensitivity of tumors to anticancer
therapy. We explored the pharmacokinetics of 5-Xuoroura-
cil in both plasma and tumor tissue during a 5-day continu-
ous infusion of 5-Xuorouracil in patients with cancer.
Sampling for measurement of 5-Xuorouracil in tumor tissue
was performed using microdialysis.
Experimental design In seven patients with an accessible
(sub)cutaneous tumor treated with a continuous 5-Xuoro-
uracil infusion, plasma and microdialysate samples from
tumor and normal adipose tissue were collected over a
period of 5 days.
Results For six patients, drug concentrations in both
tumor tissue and plasma were available. Concentration–
time curves of unbound 5-Xuorouracil were lower in tumor
tissue compared to the curves in plasma, but exposure
ratios of tumor tissue versus plasma increased during the
5-day infusion period. The presence of circadian rhythmic-
ity of 5-Xuorouracil pharmacokinetics in the tumor itself
was demonstrated as 5-Xuorouracil concentrations in tumor
extracellular Xuid were higher during the night than during
daytime.
Conclusion Microdialysis was successfully employed in
patients with cancer during a continuous 5-day 5-Xuoroura-
cil infusion. Plasma and tumor pharmacokinetics of 5-Xuo-
rouracil diVered substantially with increasing 5-Xuorouracil
concentrations in tumor over time, possibly resulting from
a lowered interstitial Xuid pressure by 5-Xuorouracil itself.
This microdialysis 5-Xuorouracil model might be useful to
monitor the eVect of drug delivery modulating strategies in
future studies.
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Introduction
Traditionally, most oncological treatment regimens and
doses are based on safety proWles. It is generally assumed
that the obtained pharmacokinetic proWle in blood is
directly related to the mentioned safety and the magnitude
of antitumor response. However, the eYcacy of anticancer
drugs will likely depend on the maintenance of adequate
unbound drug concentrations in tumor tissue rather than in
plasma. Furthermore, the pharmacokinetic proWle of a drug
in blood may not per deWnition resemble its pharmacoki-
netic proWle in tumor or normal tissue, as was demonstrated
in a mouse model [1–3]. More detailed information about
drug levels at the tumor site itself would therefore be help-
ful in optimizing oncological treatment.
In clinical oncology, evaluation of tumor and tissue dis-
position of drugs has become possible with the technique of
microdialysis. This minimally invasive sampling method is
based on the exchange of compounds from the extracellular
Xuid into perfusate, which runs through an inserted catheter,
by diVusion through a semipermeable membrane following
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Cancer Chemother Pharmacoltheir concentration gradient. No net Xuid exchange occurs
during microdialysis, so prolonged continuous sampling is
possible without interfering with the pharmacokinetic
behavior of the drug [4]. The exiting solution, the so-called
microdialysate, can be used for both pharmacokinetic and
pharmacodynamic analyses.
The clinical use of microdialysis to evaluate drug dispo-
sition in tumors is of considerable interest with the recogni-
tion that insuYcient drug penetration into the interstitium
of solid tumors may be involved in resistance to anti-tumor
drugs [5, 6]. One of the problems associated with eYcient
drug delivery is the presence of increased interstitial Xuid
pressure, a phenomenon occurring in most solid tumors [7].
To date, several studies have been performed applying the
microdialysis technique in clinical oncology with several
anticancer drugs [8–14]. In most of these studies, the col-
lected data covered only a relatively short period of time,
i.e., up to a maximum of 4 h (h), which might not be ade-
quate to obtain useful pharmacokinetic proWles for many
drugs. However, recently, we showed the feasibility of
prolonged microdialysis sampling up to 48 h in ambulant
cancer patients treated with intravenous (iv) bolus carbo-
platin [15].
In the present study, we investigated the feasibility of
microdialysis for even a longer period of time using another
drug, namely 5-Xuorouracil infused continuously for
5 days. The aim was to accomplish a model that could be
used in further studies to monitor the inXuence of co-
administration of other agents on tumoral 5-FU concentra-
tions, each patient being its own control. 5-Fluorouracil
belongs to the group of the antimetabolites and is a widely
used agent for the treatment of colorectal, breast and head
and neck cancer [16–18]. After entering the tumor cell,
5-Xuorouracil is converted into several metabolites that
exert anti-tumor activity by interfering with DNA synthesis
and DNA repair and by incorporation in RNA. The major-
ity of 5-FU is inactivated by the enzyme dihydropyrimidine
dehydrogenase (DPD), which is mainly found in the liver
but also in other tissues such as the gastrointestinal
mucosa, peripheral blood cells and tumor tissue [19].
Numerous dose regimens exist, continuous administration
at 1,000 mg/m2/daily for 5 days being one of the most com-
monly used. Given the fact that 5-Xuorouracil rapidly
reaches a steady state in plasma during continuous infusion,
it was expected that 5-Xuorouracil concentrations could be
quantitated in the microdialysates during the whole 5 times
24-h period.
The aims of the present study were to explore the feasi-
bility of continuous microdialysis sampling over a 5-day
period, to assess diVerences in plasma and tumor pharmaco-
kinetics of 5-Xuorouracil during a continuous 5-Xuorouracil
infusion and to set up a clinical model, with 5-Xuorouracil
as model drug, for future drug delivery modulating studies.
Patients and methods
Patient selection criteria
Patients who had a (sub)cutaneous primary tumor or metas-
tasis and for whom 5-Xuorouracil-based therapy was con-
sidered a viable treatment option were eligible for the
study. The (sub)cutaneous lesion had to be of suYcient size
(i.e., ¸20 mm) and readily accessible for catheter implanta-
tion. Other inclusion criteria included: no use of therapeutic
doses of anti-coagulants (prophylactic use was allowed);
WHO performance status ·1; age ¸18 years; absolute neu-
trophil count ¸1.5 £ 109/l; absolute platelet count ¸100 £
109/l; creatinine clearance ¸60 ml/min; no other serious
illness or medical unstable condition requiring treatment or
a history of psychiatric disorder that would prohibit the
understanding and giving of informed consent. This single-
center study was approved by the ethical committee of the
Erasmus Medical Center (Rotterdam, the Netherlands) and
was performed in accordance with standards laid down in
the 1964 Declaration of Helsinki and its later amendments.
All patients gave written informed consent. (EudraCT
number: 2006-001070-24).
Administration of 5-Xuorouracil
5-Fluorouracil (EbeXuoro, EBEWE Pharma, Belgium) was
started as a 5-day continuous intravenous infusion on day 1,
at a dose of 1,000 mg/m2/day. To prevent allergic reactions,
nausea and vomiting, a premedication schedule consisting
of dexamethasone and granisetron was administered intra-
venously prior to the start of the 5-Xuorouracil infusion. In
case 5-Xuorouracil was combined with another cytotoxic,
this second agent was administered only on the last day of
treatment.
Plasma pharmacokinetic and microdialysis sampling
were performed during a single treatment course of Wve
days.
Microdialysis procedures
The microdialysis catheters (CMA 63 catheters, mem-
brane length 10 mm, molecular weight cut-oV level of
»20,000 Da), pumps (CMA 107, Xow rate adjustable) and
microdialysis consumables were purchased from CMA/
Microdialysis AB (Solna, Sweden). On day 0, each patient
had one microdialysis catheter inserted in a suitable (sub)cuta-
neous tumor lesion and a second one into healthy abdominal
subcutaneous adipose tissue. Catheter insertion procedures
have previously been described in detail [20]. The intratu-
moral location of the probe tip was veriWed by ultrasound.
As microdialysis is not performed under equilibrium
conditions, the concentration of the drug in the dialysate123
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probe [21]. To correct for this diVerence, the relative recov-
ery of each probe was assessed the morning after the
implantation of the probes by retrodialysis with 1 g/ml of
5-FU in Ringer’s solution as described recently [15], at a
Xow rate of 0.5 l/min (i.e., the Xow rate as used during the
pharmacokinetic sampling).
Prior to the clinical study, in vitro recovery experiments
(data not shown) were conducted to demonstrate that
5-Xuorouracil does not irreversibly bind to the catheters, the
probe recovery is independent of the concentration and is
equal in both directions over the probe, similar to previous
studies [15].
During the pharmacokinetic experiment, samples were
collected during the following sample periods: 0–2 h, 2–5 h
following the start of infusion and subsequently every 5 h
till the end of infusion at day 5. The 5-hour interval was
chosen as at a Xow rate of 0.5 l/min, the vials could not be
overWlled during this period. Samples were stored directly
at the bedside of the patient at T < ¡20°C. The dialysates
were collected by centrifugation of the microvials upside
down in micro-centrifuge reaction vials for 1 min at 500g,
after which they were stored at T < ¡20°C until analysis.
Blood sampling
For 5-Xuorouracil plasma pharmacokinetic analysis, blood
samples were collected in the presence of lithium heparin
as anticoagulant at the following time points: before start of
the infusion, 1, 2, 4, 7 and 12 h after the start of infusion
and subsequently every 12 h till the end of infusion at
day 5. Within 15 min after collection, plasma was separated
by centrifugation at 3,000g for 10 min and stored at
T < ¡20°C until analysis.
Unbound fraction in plasma
Although the free fraction of 5-Xuorouracil has been
reported to be >90% [22], and plasma protein binding will
have a minor inXuence on the tissue distribution, the per-
centage binding may be diVerent between patients. There-
fore, we estimated the free fraction of 5-Xuorouracil in each
individual patient. Aliquots of 250 l of plasma samples
collected each 24 h during the infusion period were trans-
ferred into Microcon Ultracel YM-30 Centrifugal Filter
Devices (Millipore Corp., Bedford, MA, USA) with a
molecular weight cut-oV level of 30,000 Da. The samples
were centrifuged in a Wxed angle rotor at 18,000g for
30 min. The ultraWltrate was stored at T < ¡20°C until
analysis. The individual observed concentration in each
sample was divided by the total concentration. The mean
free fraction was subsequently used to estimate the free
fraction in all samples collected.
5-Fluorouracil analysis
5-Fluorouracil (molecular weight 130.1) in the dialysate
(and ultraWltrate) was quantitated using liquid chromatogra-
phy (LC) with tandem mass spectrometric detection (MS/
MS). BrieXy, a volume of 25 l of the internal standard
solution containing 500 ng/ml 5-chlorouracil in water was
added to 25 l of dialysate, from which aliquots of 25 l
were injected into the LC (Model 2795 XC chromatograph,
Waters Alliance, Mildford, MA). Chromatographic separa-
tions were achieved on a Hypercarb column (100 £ 3 mm
internal diameter, 5 m particle size, Thermo, Breda, the
Netherlands), which was held at T = 40°C. The mobile
phase was composed of water and acetonitrile and was
delivered using a linear gradient setting. The initial Xow
rate was 0.75 ml/min where the composition changed from
10% to 90% acetonitrile in 1 min. In the subsequent min-
ute, the Xow rate was linearly decreased to 0.25 ml/min and
kept at this rate for 6 min at this rate. Subsequently, the
Xow rate was linearly increased to 1.0 ml/min in 1 min and
kept at 1.0 ml/min for 2 min. Hereafter, the composition
changed from 90% to 10% acetonitrile in 1 min. The over-
all run time was 12 min. Detection was performed with a
Waters MicroMass Quatro Micro triple-quadropole mass
spectrometer in the negative ion mode. The detector was
programmed to allow the [MH]¡ ions of 5-Xuorouracil (m/z
129) and 5-chlorouracil (m/z 145) to pass through the Wrst
quadropole and into the collision cell. The collision energy
for collision-induced dissociation of 5-Xuorouracil and
5-chlorouracil was set at 20 eV and 18 eV, respectively,
with argon used as collision gas at a pressure of 6e¡3 mbar.
The daughter ions of 5-FU (m/z 86) and 5-chlorouracil (m/z
102) were monitored through the third quadropole. The
dwell time per channel for data collection was 0.150 s.
Retention times of Xuorouracil and 5-chlorouracil were 2.5
and 3.3 min, respectively. Calibration curves were linear
from 10.0 to 1,000 ng/ml. The accuracy ranged from 94.0
to 103.7%, the within-run precisions were ·12.9% and the
between-run precisions were ·2.7% at Wve tested concen-
trations, including the lower limit of quantitation of
10.0 ng/ml.
Plasma 5-Xuorouracil concentrations were quantitated
likewise. Aliquots of 30 l plasma were extracted, after the
addition of 10 l of 500 ng/ml 5-chlorouracil, with 1.5 ml
ethyl acetate. Following vigorous vortex mixing for 5 min
and centrifugation for 5 min at 18,000g, the clear superna-
tant was evaporated to dryness at T = 70°C under nitrogen.
The residue was resuspended in 100-l aliquots of Ringer’s
solution, from which an aliquot of 50 l was injected into
the system as described earlier. LC–MS/MS system settings
were as described for dialysate. Calibration curves were lin-
ear from 20.0 to 2,000 ng/ml. The accuracy ranged from
94.4 to 107.5%, the within-run precisions were ·7.1% and123
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centrations, including the lower limit of quantitation of
20.0 ng/ml.
During the analysis of the dialysates of the Wrst 3
patients, a signiWcant matrix eVect was observed for 5-chlo-
rouracil. The observed peak areas of 5-chlorouracil were
signiWcantly lower in dialysate samples compared to the
Ringer’s solution in which the calibration curve standard
and quality control samples were prepared. This results in
an overestimation of the 5FU concentrations in the ECF.
By replacing the internal standard 5-chlorouracil by stable
13C/15N2-labeled 5-Xuorouracil, which elutes at the same
time from the analytical column as 5FU, this to mass spec-
trometry related potentially occurring issue was resolved.
Multiple reaction monitoring of 13C/15N2 5-Xuorouracil was
applied at m/z 132 > 88, with the cone voltage and collision
energy set at 30 and 18 eV, respectively.
Individual pharmacokinetic parameters were estimated
using non-weighted non-compartmental analysis using the
software program WinNonLin 5.2 (Pharsight, CA, USA).
As an increase in the ECF/plasma ratios was observed over
time, partial AUCs were then calculated over 24-h inter-
vals. Although sampling time points were not based on a
24-h cycle, the use of WinNonLin 5.2 allows for interpola-
tion of AUCs.
Results
Patients
Seven patients were included in the study between April
2008 and November 2009, of which six patients were
assessable for pharmacokinetic analysis of 5-Xuorouracil in
the extracellular Xuid of tumor tissue. One patient (No 2)
was not evaluable as there was not enough microdialysate
left for re-analysis following the switch of the internal stan-
dard in the bioanalytical methodology. Only one patient
(No 4) was evaluable for the analysis of extracellular Xuid
of normal tissue as probe recovery in the other patients was
variable. In two patients (No 1 and 6), treatment of 5-FU
was combined with carboplatin, which was administered on
the last day of treatment after termination of the 5-FU infu-
sion. A summary of demographic characteristics of the six
patients assessable for pharmacokinetic analysis in the
extracellular Xuid of tumor tissue is presented in Table 1.
Probe recovery
The in vitro recovery was independent of the concentra-
tions tested and the method applied (i.e., retrodialysis or
extraction recovery). Furthermore, the in vitro recovery
was constant over up to 10 studied days and showed that 5-
Xuorouracil does not bind to the microdialysis catheter. For
instance, at a Xow rate of 1.0 l/min, the recovery was 91
(§2.2), 82 (§0.5) and 91 (§0.2) % on days 1, 4 and 10,
respectively. In addition, as increased interstitial Xuid pres-
sure is a well-known characteristic of several tumors
[7, 23], we tested whether increased pressures inXuenced
the recovery. Pressures up to 15 mm Hg (i.e., 20 cm of
Ringer’s solution above the probe) had no eVect on the
recovery of 5-Xuorouracil.
At a Xow rate of 0.5 l/min, the in vivo recovery in the
six patients evaluable for tumor tissue drug levels varied
from 40 to 92% (Table 2) and was constant in each individ-
ual patient.
Pharmacokinetics
A summary of the pharmacokinetic data is presented in
Table 2. As also depicted in Figs. 1 and 2, the 5-Xuorouracil
concentrations in the extracellular Xuid of tumors are lower
than the concentrations of unbound 5-Xuorouracil in the
plasma compartment. Over time, however, the diVerence
between tumor and plasma concentrations decreased, as a
result of increased tumor concentrations.
Figure 3 depicts the 5-Xuorouracil concentrations in
tumor extracellular Xuid according to the time of sampling
during the day. The tumoral 5-Xuorouracil concentrations
were higher during the night than during daytime. Of note,
tumor ECF was not available from patient 3 at later time
points due to the signiWcant matrix eVect observed for
5-chlorouracil during the initial analysis and the inability
for re-analysis of the samples (all used).
Table 1 Patient demographics 
of the six patients Patient Age Gender Tumor type Tumor probe site
a
1 60 M Melanoma Leg
3 66 M Esophageal carcinoma Cervical lymph node
4 52 F Non-small cell lung cancer Abdominal wall
5 59 M Melanoma Axilla
6 49 F Muco-epidermoid carcinoma Cervical tumor mass
7 59 F Breast Supraclavicular lymph node
a Probes in subcutaneous 
normal adipose tissue were all 
placed in the abdomen123
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Optimization of cancer therapy by enhancing drug delivery
has become of major interest as many barriers to drug
delivery are being identiWed, underlining the need for new
therapeutic strategies increasing drug delivery to tumors.
Obviously, this requires a model that can easily be applied
in clinical practice and with the ability to monitor intratu-
moral drug concentrations. The present study addresses this
need and proposes the use of microdialysis to obtain
detailed information on drug concentrations at the tumor site.
Earlier studies explored the applicability of microdialysis in
clinical oncology with microdialysate collection with a
maximum of up to 48 h after iv bolus administration of car-
boplatin [15]. In this study, we showed that microdialysis is
also feasible for longer periods of time in cancer patients
treated with continuous 5-Xuorouracil infusion during a
5 £ 24 h period.
Our results evidently show lower concentration–time
curves at the tumor site in comparison with plasma. This is
in line with the results of an earlier microdialysis study by
Müller et al. where the obtained area under the curve
(AUC) in tumor after a single iv administration of 5-Xuoro-
uracil was 61% of the AUC in plasma [8]. A remarkable
observation in our study is the fact that the diVerence
between plasma and tumor concentrations diminished over
time, as a result of increasing 5-Xuorouracil concentrations
in the tumor. A possible explanation for this phenomenon
may be a change in interstitial Xuid pressure in the tumor.
Many solid malignancies display a high interstitial Xuid
pressure, which causes poor uptake of anticancer drugs and
has been associated with poor clinical response to treatment
[5, 7]. Mechanisms involved yielding a high interstitial
Xuid pressure in tumors are a high vessel permeability,
inadequate lymphatic drainage, Wbrosis and contraction of
the interstitial matrix and a high cell density around the
blood vessels [7]. Reducing tumoral interstitial Xuid pres-
sure is an attractive means to augment eYcacy of anti-
tumor drugs. In pre-clinical models, several agents have
been revealed to decrease interstitial Xuid pressure
including dexamethasone [24, 25], imatinib [26, 27] and
prostaglandin E1 [28]. Also several cytotoxic agents,
including 5-Xuorouracil, have shown to lower tumor inter-
stitial Xuid pressure within days [24, 29, 30]. Although the
decrease in tumor interstitial Xuid pressure following
4 days of 5-Xuorouracil treatment in female Sprague–
Dawley rats with induced mammary tumors was not signiW-
cantly diVerent, a reduction of 35% in interstitial Xuid
pressure was noted on day 5 compared to day 1 (7.2 vs.
4.7 mmHg; [24]). The increasing 5-Xuorouracil concentra-
tion at the tumor site as observed in our study might also be
due to the eVect of 5-Xuorouracil on the interstitial Xuid
pressure. Assuming that 5-Xuorouracil enhanced its own
tumor concentration due to its antitumor and thereby lowering
Table 2 Summary of pharmacokinetic data of 5-FU in plasma and ECF of tumor tissue
AUC area under the concentration time curve, ECF extracellular Xuid, NA not available
a Mean § SD
b Calculated using data observed during a timeframe after start of the infusion with subscript numbers referring to start and endpoint of timeframe
c AUC ratio ECFtumor/Plasmaunbound
Parameter Patient 1 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Dose 5-Xuorouracil (mg/day) 2300 1890 1700 2000 1650 1500
Plasma unbound
Fraction unbound (%)a 87 § 3.2 93 § 11 97 § 9.1 86 § 8.5 83 § 4.7 88 § 2.7
AUC0-120 (g*h/ml)a 50.8 62.7 54.6 33.6 38.6 NA
AUC0-24 (g*h/ml)b 8.79 11.1 7.39 7.22 6.25 6.56
AUC24-48 (g*h/ml)b 10.6 11.4 9.83 7.05 6.58 7.94
AUC48-72 (g*h/ml)b 10.2 11.8 12.4 6.74 7.39 NA
AUC72-96 (g*h/ml)b 10.8 14.4 13.2 5.75 8.71 NA
AUC96-120 (g*h/ml)b 10.4 14.1 11.8 6.79 9.62 NA
ECF tumor tissue
Probe recovery (%)a 40 § 4.5 89 § 3.4 89 § 2.7 92 § 2.4 63 § 1.2 92 § 1.2
AUC0–120 (g*h/ml)b,c 11.0 (0.22) NA 13.0 (0.24) 13.6 (0.41) 6.38 (0.17) 19.3 (NA)
AUC0–24 (g*h/ml)b,c 1.31 (0.15) 1.69 (0.15) 0.92 (0.12) 2.09 (0.29) 0.94 (0.15) 2.61 (0.40)
AUC24–48 (g*h/ml)b,c 1.70 (0.16) 2.59 (0.23) 2.03 (0.21) 2.43 (0.35) 1.13 (0.17) 3.51 (0.44)
AUC48–72 (g*h/ml)b,c 2.23 (0.22) 2.60 (0.22) 2.49 (0.20) 2.96 (0.44) 1.24 (0.17) 5.05 (NA)
AUC72–96 (g*h/ml)b,c 2.73 (0.25) NA 3.82 (0.29) 2.85 (0.50) 1.50 (0.17) 4.28 (NA)
AUC96–120 (g*h/ml)b,c 3.03 (0.29) NA 3.69 (0.31) 3.26 (0.48) 1.58 (0.16) 3.87 (NA)123
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with a recent study showing that modulation of convection
currents by lowering interstitial Xuid pressure by treatment
with collagenase within tumors enhances the delivery of
5-Xuorouracil approximately 1.5-fold [31]. The transport of
low-molecular weight compounds, such as 5-Xuorouracil,
from the vascular space into the interstitial space is thus also
driven by convection besides by diVusion. Though only
available for one patient, 5-Xuorouracil uptake in normal tis-
sue does not seem to increase over time. In the patient with
evaluable pharmacokinetic data in extracellular Xuid of nor-
mal tissue, the tumor exposure increased, while normal tissue
exposure was constant over time (Figs. 1 and 2). This is also
in agreement with the aforementioned study [31], which did
not show a diVerence in 5-Xuorouracil accumulation in nor-
mal tissue of mice treated with or without collagenase, i.e.,
with or without lowering of interstitial Xuid pressure.
The interstitial Xuid pressure and its eVect on convention
currents are only two of the multiple factors inXuencing
drug delivery at the target site. Tumor vasculature diVers
signiWcantly from that of normal tissue, with great hetero-
geneity in density, length and diameter, thereby impeding
blood Xow. Tumor pH gradients are of importance too,
as membrane transport and accumulation of weakly acidic
5-Xuorouracil in tumors is pH dependent [6, 32, 33]. DPD
activity may be of inXuence as well, since its activity is
known to be variable in tumor tissue and dysregulation of
DPD is more frequent in malignant tissue [19, 34]. These
tumor-speciWc characteristics may explain the diVerences
observed in ECFtumor/plasmaunbound ratio’s between the
patients.
Similar to the Wndings of our previous microdialysis
study in carboplatin-treated patients measurement of
5-Xuorouracil in extracellular Xuid of normal adipose tissue
was troublesome because of Xuctuating recovery assess-
ments [15]. It is well conWrmed now that subcutaneous adi-
pose tissue is not the best site to use as control, most
probably due to its diVerent and poorer vascularization.
Other normal tissues should be chosen as site control in
future studies, e.g., muscular tissue or preferably, tissue
surrounding the tumor.
Another interesting observation was the typical pharma-
cokinetic pattern of 5-Xuorouracil, with higher 5-Xuoroura-
cil tumor extracellular Xuid concentrations observed during
the night compared to daytime (Fig. 3). Circadian rhyth-
micity of 5-Xuorouracil pharmacokinetics in plasma has
been an issue of investigation for decades. During continu-
ous 5-Xuorouracil infusion, 5-Xuorouracil plasma concen-
trations turned out to be higher during the night than during
daytime. Many factors such as age, diet, physical activity,
high serum alkaline phosphatase and length of drug infu-
sion were previously identiWed as patient variables aVecting
5-Xuorouracil clearance [34, 35]. Also, dihydropyrimidine
Fig. 1 Concentration–time curves of the unbound fraction of 5-FU in
plasma (open circles) and extracellular Xuid (ECF) of tumor (Wlled
black circles) and ECF of normal adipose tissue (Wlled gray circles) in
the six evaluable patients
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Cancer Chemother Pharmacoldehydrogenase activity has been found to change during the
day, with its highest activity occurring during daytime [34].
In order to achieve the highest eYcacy and least toxicity,
chronomodulated 5-Xuorouracil therapy was developed,
albeit not regarded standard of care yet [35, 36]. Our study
is the Wrst to suggest the presence of a circadian rhythm of
5-Xuorouracil pharmacokinetics in the tumor itself.
In summary, we showed the feasibility of microdialysis
in cancer patients treated with a continuous 5-Xuorouracil
infusion during a 5 £ 24 h period. Plasma levels of 5-Xuo-
rouracil were higher compared to tumor, but there was a
distinct rise of 5-Xuorouracil at the tumor site over time.
Since 5-Xuorouracil is a widely used cytotoxic agent and
high concentrations at the tumor site are directly linked
with a better response [6, 8], evaluation of its disposition in
tumor tissue is of notable importance to further optimize
individual cancer patient treatment. The technique of
microdialysis can be used to improve insight into processes
involved in tumor pharmacokinetics, such as interstitial
Xuid pressure. In a rat model, the co-administration of
imatinib resulted in a signiWcant decrease in interstitial Xuid
pressure with as a consequence a two to fourfold increase
of the ECFtumor/plasmaunbound ratio’s of 51Cr-EDTA and
paclitaxel, respectively, and a signiWcant tumor volume
reduction of 44% in rats treated with 5-FU and imatinib
[26, 27]. Clinical trials investigating the impact of
co-administration of drugs thought to (in)directly eVect
tumor drug uptake in patients with cancer are warranted,
and this microdialysis model, with 5-Xuorouracil as repre-
sentative drug for other small molecules, might be a useful
tool to study pharmacokinetics and pharmacodynamics in
more detail. The ongoing development of newer microdialy-
sis probes that can be used in deeper-lying (tumor) tissue,
e.g., the liver, will add to the clinical use of this technique.
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